Vaccine sa_老虎社区_美港股上老虎

Annalz
2021-12-20

Vaccine saving the world

Novavax expected to start delivering COVID-19 shots to EU in first quarter 2022 -EU source

BRUSSELS, Dec 20 (Reuters) - Novavax(NVAX.O)is expected to start delivering its COVID-19 vaccines to

Novavax expected to start delivering COVID-19 shots to EU in first quarter 2022 -EU source

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":693650187,"tweetId":"693650187","gmtCreate":1640015639173,"gmtModify":1640015639669,"author":{"id":3577089953267281,"authorId":3577089953267281,"authorIdStr":"3577089953267281","name":"Annalz","avatar":"https://static.tigerbbs.com/ffd285ab6189bb61da4b48c3e149eedc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Vaccine saving the world&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Vaccine saving the world&nbsp;</p></body></html>","text":"Vaccine saving the world","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693650187","repostId":1102066717,"repostType":4,"repost":{"id":"1102066717","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639998810,"share":"https://www.laohu8.com/m/news/1102066717?lang=&edition=full","pubTime":"2021-12-20 19:13","market":"us","language":"en","title":"Novavax expected to start delivering COVID-19 shots to EU in first quarter 2022 -EU source","url":"https://stock-news.laohu8.com/highlight/detail?id=1102066717","media":"Reuters","summary":"BRUSSELS, Dec 20 (Reuters) - Novavax(NVAX.O)is expected to start delivering its COVID-19 vaccines to","content":"<p>BRUSSELS, Dec 20 (Reuters) - Novavax(NVAX.O)is expected to start delivering its COVID-19 vaccines to the European Union in the first quarter of 2022, an EU source said, as experts for the region's drug regulator met on Monday to decide whether to approve the shot.</p>\n<p>The EU Commission had no immediate comment and the U.S. biotech company was not immediately available for comment. The EU source declined to be identified because they were not authorised to speak to the media.</p>\n<p>If approved, the two-dose vaccine, branded Nuvaxovid, would be the fifth coronavirus shot to be brought on to the EU market and arrives as the Omicron coronavirus variant spreads.</p>\n<p>Earlier in the year, Novavax had told the European Union it planned to begin making first small shipments of its vaccine for the bloc towards the end of this year, with the bulk of supplies in 2022, an EU official told Reuters in May.</p>\n<p>The EU Commission and the company signed a contract in August for the delivery of up to 200 million doses, of which half is optional.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax expected to start delivering COVID-19 shots to EU in first quarter 2022 -EU source</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax expected to start delivering COVID-19 shots to EU in first quarter 2022 -EU source\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-20 19:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BRUSSELS, Dec 20 (Reuters) - Novavax(NVAX.O)is expected to start delivering its COVID-19 vaccines to the European Union in the first quarter of 2022, an EU source said, as experts for the region's drug regulator met on Monday to decide whether to approve the shot.</p>\n<p>The EU Commission had no immediate comment and the U.S. biotech company was not immediately available for comment. The EU source declined to be identified because they were not authorised to speak to the media.</p>\n<p>If approved, the two-dose vaccine, branded Nuvaxovid, would be the fifth coronavirus shot to be brought on to the EU market and arrives as the Omicron coronavirus variant spreads.</p>\n<p>Earlier in the year, Novavax had told the European Union it planned to begin making first small shipments of its vaccine for the bloc towards the end of this year, with the bulk of supplies in 2022, an EU official told Reuters in May.</p>\n<p>The EU Commission and the company signed a contract in August for the delivery of up to 200 million doses, of which half is optional.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102066717","content_text":"BRUSSELS, Dec 20 (Reuters) - Novavax(NVAX.O)is expected to start delivering its COVID-19 vaccines to the European Union in the first quarter of 2022, an EU source said, as experts for the region's drug regulator met on Monday to decide whether to approve the shot.\nThe EU Commission had no immediate comment and the U.S. biotech company was not immediately available for comment. The EU source declined to be identified because they were not authorised to speak to the media.\nIf approved, the two-dose vaccine, branded Nuvaxovid, would be the fifth coronavirus shot to be brought on to the EU market and arrives as the Omicron coronavirus variant spreads.\nEarlier in the year, Novavax had told the European Union it planned to begin making first small shipments of its vaccine for the bloc towards the end of this year, with the bulk of supplies in 2022, an EU official told Reuters in May.\nThe EU Commission and the company signed a contract in August for the delivery of up to 200 million doses, of which half is optional.","news_type":1},"isVote":1,"tweetType":1,"viewCount":556,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":21,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}